Facilitated By

San Antonio Medical Foundation

A Randomized, Multicenter, Open-Label, Phase 3 Study To Compare The Efficacy And Safety Of Acalabrutinib (ACP-196) In Combination With Venetoclax With And Without Obinutuzumab Compared To Investigator's Choice Of Chemoimmunotherapy In Subjects With Previously Untreated Chronic Lymphocytic Leukemia Without DEL(17P) Or TP53 Mutation

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
HJF
Research Start Date
Status
Active

The primary objective of the study is to evaluate the efficacy of Acalabrutinib with Venetoclax compared with standard of care chemoimmunotherapy for progression free survival

Collaborative Project
Clinical Care
Cancer
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.